Today's Rundown ASH18: J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab Regeneron records 80% complete response rate in lymphoma trial ASH18: New data can’t lift Bluebird Bio’s depressed shares Celgene’s luspatercept aces phase 3 beta thalassemia trial Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH Special Report—The top 10 medtech companies of 2024 Featured Story | | | Monday, December 3, 2018 As the biggest and brightest in the blood cancer world assembled at the ASH conference this weekend, European biotech Argenx was busy making a big deal with Johnson & Johnson's Janssen unit, nabbing $500 million in upfront cash plus up to $1.3 billion in potential milestones. |
|
|
Top Stories Monday, December 3, 2018 Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma. The strong early signs of efficacy led Regeneron to target a 2019 start date for a potentially registrational phase 2 study. Monday, December 3, 2018 Bluebird Bio has been singing the praises of two new therapies at ASH, but although the data look solid so far, investors don’t seem to be fully on board with the program. Monday, December 3, 2018 A phase 3 trial of Celgene’s luspatercept in adults with beta thalassemia has hit its primary goal. The late-phase success tees Celgene to file for approval of its Acceleron-partnered blockbuster prospect in the first half of next year. Friday, November 30, 2018 At the closely watched American Society of Hematology annual meeting, Fate Therapeutics will present preclinical data on three investigational cell therapies the company is developing as off-the-shelf therapies. Fate's method of producing cancer-fighting cells from stem cells could sidestep the high costs associated with personalized CAR-T therapies, the company's executives argue. Monday, December 3, 2018 While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and reap billions in additional sales in new market segments. Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Approval, Manufacturing Quality & Regulation 2018 | Online FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore | 